NCT03742037: A reported trial by Idorsia Pharmaceuticals Ltd.
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT03742037 |
---|---|
Title | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE) |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Dec. 21, 2018 |
Completion date | Aug. 31, 2021 |
Required reporting date | Aug. 31, 2024, midnight |
Actual reporting date | Aug. 7, 2023 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |